Early access to medicines scheme (EAMS) scientific opinion: Nivolumab to treat a type of cancer of the lymph system
EAMS scientific opinion given to Nivolumab to treat a type of cancer of the lymph system, including the public assessment report.
Documents
Details
This positive scientific opinion was issued to Bristol-Myers Squibb Pharmaceuticals Limited for Nivolumab to treat a type of cancer of the lymph system.
The scientific opinion includes:
- a public assessment report
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
Contact
Information and details regarding patient access
For patients wishing to access nivolumab, Trusts must complete a Blueteq form to register each patient with NHS England. The Blueteq registration number provided by NHS England will be used in all communication with BMS for the patient including completion of initial drug supply and re-supply case report forms and reporting adverse events. Further information regarding this can be requested from the dedicated EAMS email address: england.eams@nhs.net.
For information about access in Northern Ireland, contact Mark Timoney, Chief Pharmaceutical Officer at Mark.Timoney@dhsspsni.gsi.gov.uk and Joe Magee, Secondary Care Directorate at Joe.Magee@dhsspsni.gov.uk.
For information about access in Scotland contact the Scottish Government Directorate General Health & Social Care email John.Hannah@gov.scot and elisabeth.campbell@gov.scot
For information about access in Wales, contact the Welsh Government Department of Health and Social Services by emailing Andrew Evans, Interim Chief Pharmaceutical Officer at Andrew.Evans@wales.gsi.gov.uk and Karen Eveleigh, Head of Pharmacy and Prescribing policy at Karen.Eveleigh@wales.gsi.gov.uk.
Last updated 8 November 2016 + show all updates
-
Updated information for patients wishing to access nivolumab.
-
Updated treatment protocol for healthcare professionals.
-
First published.